CYTOSORBENTS CORP's ticker is CTSO and the CUSIP is 23283X206. A total of 90 filers reported holding CYTOSORBENTS CORP in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $140,000 | -10.8% | 33,313 | +72.8% | 0.00% | – |
| Q3 2021 | $157,000 | -72.4% | 19,279 | -74.4% | 0.00% | -100.0% |
| Q2 2021 | $569,000 | -47.7% | 75,354 | -39.9% | 0.00% | -66.7% |
| Q1 2021 | $1,088,000 | +77.5% | 125,316 | +62.9% | 0.00% | +50.0% |
| Q4 2020 | $613,000 | -40.7% | 76,931 | -40.6% | 0.00% | -50.0% |
| Q3 2020 | $1,033,000 | +39.0% | 129,558 | +72.7% | 0.00% | 0.0% |
| Q2 2020 | $743,000 | +77.8% | 75,019 | -31.0% | 0.00% | +300.0% |
| Q4 2019 | $418,000 | +248.3% | 108,693 | +499.5% | 0.00% | – |
| Q2 2019 | $120,000 | -68.9% | 18,132 | -64.5% | 0.00% | -100.0% |
| Q1 2019 | $386,000 | +42.4% | 51,022 | +52.1% | 0.00% | 0.0% |
| Q4 2018 | $271,000 | +53.1% | 33,545 | +144.8% | 0.00% | – |
| Q3 2018 | $177,000 | -91.9% | 13,702 | -92.9% | 0.00% | -100.0% |
| Q2 2018 | $2,188,000 | +228.0% | 191,933 | +102.9% | 0.01% | +250.0% |
| Q1 2018 | $667,000 | – | 94,613 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CM Management, LLC | 450,000 | $846,000 | 0.90% |
| Skylands Capital, LLC | 2,944,670 | $5,535,980 | 0.84% |
| Sargent Investment Group, LLC | 1,257,048 | $2,363,250 | 0.57% |
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 197,940 | $372,127 | 0.52% |
| Avenir Corp | 2,717,397 | $5,108,706 | 0.48% |
| Granahan Investment Management | 1,552,393 | $2,918,499 | 0.10% |
| Seelaus Asset Management LLC | 20,450 | $38,446 | 0.04% |
| HighMark Wealth Management LLC | 10,000 | $18,800 | 0.02% |
| Key Client Fiduciary Advisors, LLC | 13,000 | $24,440 | 0.02% |
| Eudaimonia Partners, LLC | 23,500 | $44,180 | 0.01% |